Article info
Original research
‘Delusional’ consent in somatic treatment: the emblematic case of electroconvulsive therapy
- Correspondence to Dr Angela Iannitelli, Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila Department of Clinical Sciences and Applied Biotechnology, 67100 L'Aquila, Italy; iannitelliangela{at}gmail.com
Citation
‘Delusional’ consent in somatic treatment: the emblematic case of electroconvulsive therapy
Publication history
- Received April 26, 2019
- Revised December 17, 2019
- Accepted January 10, 2020
- First published February 13, 2020.
Online issue publication
May 29, 2020
Article Versions
- Previous version (13 February 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Electroconvulsive therapy: a life course approach for recurrent depressive disorder
- Electroconvulsive therapy, catatonia, deep vein thrombosis and anticoagulant treatment: a case report
- Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?
- Informed consent and ECT: how much information should be provided?
- Electroconvulsive therapy, the placebo effect and informed consent
- Current status of electroconvulsive therapy for mood disorders: a clinical review
- New guidance on ECT looks set to curb its use
- Complete cognitive recovery in a severe case of anti-N-methyl-d-aspartate receptor encephalitis treated with electroconvulsive therapy
- Successful electroconvulsive therapy for depression in a man with cerebral amyloid angiopathy
- Worsening of movement disorder following treatment with electroconvulsive therapy in a patient with Huntington’s disease